Back to Awarded Treatment Trials


Awarded Trial: 07TGS-1082

Grant ID

07TGS-1082

Illness

Schizophrenia

Primary Drug/Intervention

Cannabidiol

Primary Dosage

600 mg/day

Secondary Drug Intervention

N/A

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Ranganathan

Sample Size

36

Duration of Study Period for Each Subject

42 days

Outcome Measurements

PANSS, MATRICS Consensus Cognitive Battery, HVLT, BMI, VAS

Results

This study randomized 36 patients with schizophrenia or schizoaffective disorder, stabilized on anti-psychotics, between the ages of 18-65, to add-on 600 mg/day cannibidiol or placebo for six weeks. No improvement in verbal short-term memory was detected by HVLT Total Immediate Recall, and no improvement in attention or cognition was detected by MATRICS Cognitive Consensus Battery (MCCB). There were no significant effects on smoking, movement, or depression.

Publication

N/A

Link

N/A

PI Name

Mohini Ranganathan

Degree

MD

Center

VACHS

Institution

Yale University

Address

950 Campbell Ave, Department of Psychiatry

City or Town

West Haven

State or Province

CT

Zip or Postal Code

6516

Country

USA

Email Address

mohini.ranganathan@yale.edu